Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business context and reporting period
Arcturus Therapeutics Holdings Inc. filed a Current Report on Form 8-K dated April 21, 2023. The filing reports that its wholly owned subsidiary, Arcturus Therapeutics, Inc., entered into a revolving credit facility with Wells Fargo Bank, National Association.
Credit facility and key terms
- Facility size: $50 million revolving line of credit.
- Interest rate: 1.00% above Daily Simple SOFR or Term SOFR, as applicable.
- Default rate: 2.00% above the rate applicable immediately before an event of default.
- Term: Two years, with one-year renewal options subject to Wells Fargo approval and a non-refundable renewal commitment fee equal to 0.25% of the loan amount.
- Collateral: $55 million in cash pledged in Arcturus securities accounts held with Wells Fargo Securities, LLC, an affiliate of Wells Fargo.
- Termination: The filing states there is no penalty for terminating the agreement or the facility before maturity.
The filing does not state whether any amounts had been drawn under the facility as of April 21, 2023. It also does not provide revenue, profit, cash flow, margin, or other operating metrics.
Material changes versus the prior comparable period
This filing does not provide comparative financial results. The material development is the creation of a new $50 million revolving credit facility and related cash pledge.
Outlook, risks, contingencies, and unusual items
- The facility provides additional borrowing capacity but is secured by $55 million of cash, which may limit the immediate liquidity benefit of the arrangement.
- Borrowings expose Arcturus to variable interest rates based on SOFR and to a higher rate following an event of default.
- Renewals are subject to Wells Fargo approval and a renewal commitment fee.
- The filing states that the descriptions of the credit agreement, note, and security agreement are incomplete and refers readers to the full documents, which were to be filed in a subsequent periodic report.
- No guidance or management outlook is included.
Investor verification checklist
- Verify whether the company subsequently drew on the revolving facility and the amount outstanding.
- Review the complete credit agreement, note, and security agreement for covenants, borrowing conditions, events of default, and collateral-release provisions.
- Confirm the location, restrictions, and liquidity impact of the pledged $55 million in cash.
- Check subsequent filings for facility renewals, amendments, termination, or changes in interest rates.
- Assess interest-rate exposure and compliance with all lender requirements.